The most commonly reported adverse reactions (occurring in greater than 10% of patients) are pyrexia, chills, rash, thrombocytopenia, leukopenia and arthralgia.
Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression. Although the exact mechanism of action is unknown, equine anti-thymocyte globulin targets a variety of immune system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and other cell types. Equine ATG is currently indicated for the suppression of the immune system to prevent renal transplant rejection and in the treatment of aplastic anemia. Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for its therapeutic effect in these conditions.
There are currently various ATG products available, which differ in the source of inoculated animal (rabbit, horse, or pig) and in the type of antigen product used to produce immunoglobulin (thymocytes, peripheral T cells, etc.).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Antilymphocyte immunoglobulin (horse). |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Antilymphocyte immunoglobulin (horse). |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Antilymphocyte immunoglobulin (horse). |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Antilymphocyte immunoglobulin (horse). |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Antilymphocyte immunoglobulin (horse). |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Antilymphocyte immunoglobulin (horse). |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Antilymphocyte immunoglobulin (horse). |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Antilymphocyte immunoglobulin (horse). |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Antilymphocyte immunoglobulin (horse). |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Antilymphocyte immunoglobulin (horse). |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Antilymphocyte immunoglobulin (horse). |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antilymphocyte immunoglobulin (horse). |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Antilymphocyte immunoglobulin (horse). |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Antilymphocyte immunoglobulin (horse). |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Antilymphocyte immunoglobulin (horse). |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Antilymphocyte immunoglobulin (horse). |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Antilymphocyte immunoglobulin (horse). |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Antilymphocyte immunoglobulin (horse). |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Antilymphocyte immunoglobulin (horse). |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antilymphocyte immunoglobulin (horse). |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Antilymphocyte immunoglobulin (horse). |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Antilymphocyte immunoglobulin (horse). |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Antilymphocyte immunoglobulin (horse). |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Antilymphocyte immunoglobulin (horse). |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Antilymphocyte immunoglobulin (horse). |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Antilymphocyte immunoglobulin (horse). |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Antilymphocyte immunoglobulin (horse). |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Antilymphocyte immunoglobulin (horse). |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Antilymphocyte immunoglobulin (horse). |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Antilymphocyte immunoglobulin (horse). |
| Cladribine | Antilymphocyte immunoglobulin (horse) may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Antilymphocyte immunoglobulin (horse). |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Antilymphocyte immunoglobulin (horse). |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Antilymphocyte immunoglobulin (horse). |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Antilymphocyte immunoglobulin (horse). |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Antilymphocyte immunoglobulin (horse). |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Antilymphocyte immunoglobulin (horse). |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Antilymphocyte immunoglobulin (horse). |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Antilymphocyte immunoglobulin (horse). |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Antilymphocyte immunoglobulin (horse). |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Antilymphocyte immunoglobulin (horse). |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Antilymphocyte immunoglobulin (horse). |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Antilymphocyte immunoglobulin (horse). |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Antilymphocyte immunoglobulin (horse). |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Antilymphocyte immunoglobulin (horse). |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Antilymphocyte immunoglobulin (horse). |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Antilymphocyte immunoglobulin (horse). |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Antilymphocyte immunoglobulin (horse). |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Antilymphocyte immunoglobulin (horse). |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Antilymphocyte immunoglobulin (horse). |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Antilymphocyte immunoglobulin (horse). |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Antilymphocyte immunoglobulin (horse). |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Antilymphocyte immunoglobulin (horse). |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Antilymphocyte immunoglobulin (horse). |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Antilymphocyte immunoglobulin (horse). |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Antilymphocyte immunoglobulin (horse). |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Antilymphocyte immunoglobulin (horse). |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Antilymphocyte immunoglobulin (horse). |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Antilymphocyte immunoglobulin (horse). |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Antilymphocyte immunoglobulin (horse). |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Antilymphocyte immunoglobulin (horse). |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Antilymphocyte immunoglobulin (horse). |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Antilymphocyte immunoglobulin (horse). |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Antilymphocyte immunoglobulin (horse). |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Antilymphocyte immunoglobulin (horse). |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Antilymphocyte immunoglobulin (horse). |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Antilymphocyte immunoglobulin (horse). |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Antilymphocyte immunoglobulin (horse). |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Antilymphocyte immunoglobulin (horse). |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Antilymphocyte immunoglobulin (horse). |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Antilymphocyte immunoglobulin (horse). |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Antilymphocyte immunoglobulin (horse). |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Antilymphocyte immunoglobulin (horse). |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Antilymphocyte immunoglobulin (horse). |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Antilymphocyte immunoglobulin (horse). |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Antilymphocyte immunoglobulin (horse). |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Antilymphocyte immunoglobulin (horse). |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Antilymphocyte immunoglobulin (horse). |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Antilymphocyte immunoglobulin (horse). |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Antilymphocyte immunoglobulin (horse). |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Antilymphocyte immunoglobulin (horse). |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Antilymphocyte immunoglobulin (horse). |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Antilymphocyte immunoglobulin (horse). |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Antilymphocyte immunoglobulin (horse). |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Antilymphocyte immunoglobulin (horse). |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Antilymphocyte immunoglobulin (horse). |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Antilymphocyte immunoglobulin (horse). |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Antilymphocyte immunoglobulin (horse). |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Antilymphocyte immunoglobulin (horse). |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Antilymphocyte immunoglobulin (horse). |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Antilymphocyte immunoglobulin (horse). |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Antilymphocyte immunoglobulin (horse). |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Antilymphocyte immunoglobulin (horse). |
| Doxorubicin | The risk or severity of adverse effects can be increased when Doxorubicin is combined with Antilymphocyte immunoglobulin (horse). |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Antilymphocyte immunoglobulin (horse). |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Antilymphocyte immunoglobulin (horse). |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Antilymphocyte immunoglobulin (horse). |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Antilymphocyte immunoglobulin (horse). |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Antilymphocyte immunoglobulin (horse). |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Antilymphocyte immunoglobulin (horse). |